Dendrimers reduce toxicity of Aβ 1-28 peptide during aggregation and accelerate fibril formation

Research Projects

Organizational Units

Journal Issue

Abstract

The influence of a GATG (gallic acid-triethylene glycol) dendrimer decorated with 27 terminal morpholine groups ([G3]-Mor) on the aggregation process of Alzheimer's peptide has been investigated. Amyloid fibrils were formed from the Aβ 1-28 peptide and the process was monitored by a ThT assay, changes in CD spectra, and transmission electron microscopy. In the presence of [G3]-Mor, more fibrils were built and the process significantly accelerated compared with a control. The cytotoxicity of (1) Aβ and (2) the system [G3]-Mor/Aβ was monitored at different stages of the aggregation process. Prefibrillar species were more toxic than mature fibrils. [G3]-Mor significantly reduced the toxicity of Aβ, probably because of lowering the amount of prefibrillar forms in the system by speeding up the process of fibril formation

Description

Bibliographic citation

Klajnert, B., Wasiak, T., Ionov, M., Fernandez-Villamarin, M., Sousa-Herves, A., & Correa, J. et al. (2012). Dendrimers reduce toxicity of Aβ 1-28 peptide during aggregation and accelerate fibril formation. Nanomedicine: Nanotechnology, Biology And Medicine, 8(8), 1372-1378. doi: 10.1016/j.nano.2012.03.005

Relation

Has part

Has version

Is based on

Is part of

Is referenced by

Is version of

Requires

Sponsors

This work was funded by the project “Biological Properties and Biomedical Applications of Dendrimers” operated within Foundation for Polish Science TEAM programme, cofinanced by the European Regional Development Fund. Financial support is also acknowledged from the Spanish MICINN (CTQ2009-10963 and CTQ2009-14146-C02-02) and the Xunta de Galicia (10CSA209021PR and CN2011/037). M.F-V. thanks the Spanish Ministry of Education for a FPU fellowship. The research was performed within the frame of the COST Action TD0802 “Dendrimers for biomedical applications.”

Rights

© 2012 Elsevier B.V. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http:// creativecommons.org/licenses/by-nc-nd/4.0/)